--- title: "Why MI-PV Integration Is No Longer Optional: The Cost of Working in Silos" description: "Discover why Medical Information and Pharmacovigilance integration is essential for safety reporting, compliance, efficiency and audit readiness." url: https://qbdgroup.com/en/blog/medical-information-pharmacovigilance-integration type: "Blog post" language: en published: 2026-09-23 author: "María Corrales" category: "Pharmacovigilance" publisher: "QbD Group" citation: "QbD Group, \"Why MI-PV Integration Is No Longer Optional: The Cost of Working in Silos\", https://qbdgroup.com/en/blog/medical-information-pharmacovigilance-integration" --- # Why MI-PV Integration Is No Longer Optional: The Cost of Working in Silos > Discover why Medical Information and Pharmacovigilance integration is essential for safety reporting, compliance, efficiency and audit readiness. Medical Information (MI) and Pharmacovigilance (PV) grew up as separate functions in most pharma organisations, with different owners, different systems and often different reporting lines. That separation made sense when MI was mostly about answering label questions and PV was primarily focused on processing formal safety reports. For a long time, the overlap between the two was small enough to manage informally. It makes far less sense today. A healthcare professional (HCP) or patient calling with a routine product question can just as easily mention a side effect, a product quality issue or an off-label experience. And regulators do not distinguish between an adverse event captured through a formal PV channel and one captured through a medical inquiry. **Where the information enters the organisation may differ. The responsibility to recognise and act on it does not.** ## In This Blog Post - Why the traditional separation between MI and PV creates growing risk - What pharmacovigilance requirements mean for Medical Information teams - Where disconnected MI-PV processes can break down - Why integration matters beyond regulatory compliance - What an integrated MI-PV operating model actually looks like ## What Pharmacovigilance Requirements Mean for Medical Information The European Medicines Agency's Good Pharmacovigilance Practices, specifically GVP Module VI, sets out how suspected adverse reactions must be collected, validated and reported. There is no exception based on where inside a company the information first arrives. Unsolicited reports from healthcare professionals, patients and digital media all fall within pharmacovigilance collection and reporting requirements. Marketing authorisation holders are expected to seek the information required to appropriately assess and report a case once it surfaces, regardless of which department first receives it. In practice, this means a marketing authorisation holder's pharmacovigilance obligations extend beyond the formal PV function. They touch every function that communicates with HCPs and patients. **Medical Information very much included.** Whether or not that function was originally designed with PV reporting in mind. ## Where MI-PV Silos Actually Break Down This is where a disconnected operating model creates real exposure. If an MI professional has no clear, systematic route for escalating a potential adverse event or product quality complaint directly to PV, that information can: - sit unflagged - be logged inconsistently - lose important context during handover - or simply be missed once the interaction ends The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has published inspection metrics highlighting the importance of effective spontaneous case processing, including how adverse event reports are identified, entered, assessed and followed up. Weaknesses in the processes that connect customer-facing functions with formal pharmacovigilance systems can therefore create very real compliance exposure. This is not simply a theoretical governance problem. **A handover between MI and PV is part of the safety process itself.** ## MI-PV Integration Is More Than a Compliance Issue The cost of working in silos is not only regulatory. When Medical Information and Pharmacovigilance operate through separate systems and separate records, the same inquiry can end up being partially re-investigated by both teams because neither has complete visibility into what the other has already captured. That creates unnecessary work internally. It can also create a fragmented experience externally. Healthcare professionals and patients notice when the information they receive differs across contact points. Inconsistent or contradictory responses can erode trust at exactly the moment when a pharmaceutical company needs to appear reliable. At the same time, PV teams can lose access to a potentially valuable source of early insight. Medical inquiries may reveal: - emerging questions - unexpected patterns of product use - recurring concerns - areas where HCPs or patients need additional clarification These patterns can become more useful when Medical Information and Pharmacovigilance data are considered together rather than in isolation. **Integration therefore improves more than compliance. It improves visibility.** ## What Effective MI-PV Integration Actually Looks Like A well-integrated MI-PV model does not mean merging Medical Information and Pharmacovigilance into one undifferentiated team. Their responsibilities and expertise remain distinct. Integration means deliberately building the connective tissue between them. That includes: - a clear and trained process for MI staff to recognise and flag a potential adverse event or product complaint as soon as it surfaces - a direct, documented handover to Pharmacovigilance without relevant information being lost in translation - shared or interoperable systems that allow both teams to understand the full context of an interaction - clearly defined responsibilities and escalation pathways - joint oversight of documentation and process performance - consistent traceability and audit readiness across both functions The goal is not to make every Medical Information professional a Pharmacovigilance specialist. It is to make sure they know **when safety-relevant information has entered the conversation, what needs to happen next, and who owns that next step.** Done well, this is not extra bureaucracy. It is the difference between treating safety information as something the organisation is collectively equipped to recognise and treating it as one department's responsibility that everyone else occasionally stumbles into. ## Why MI-PV Integration Matters More as Inquiry Volumes Rise As medical inquiry volumes rise and products become more complex, the cost of keeping Medical Information and Pharmacovigilance disconnected grows with them. More inquiries mean more opportunities for safety-relevant information to surface. More channels mean more potential entry points into the organisation. And increasing regulatory scrutiny leaves less room for information to become delayed, fragmented or lost between functions. The question is therefore no longer simply whether MI and PV communicate with each other. It is whether the operating model makes that communication **systematic, documented and reliable.** ## Build Medical Information and Pharmacovigilance Around the Same Safety Reality Medical Information and Pharmacovigilance do not need to become the same function. But they do need to operate as connected parts of the same safety ecosystem. That means designing processes, systems and governance around the reality that safety-relevant information can enter through any interaction with an HCP or patient, not only through a dedicated Pharmacovigilance channel. As inquiry volumes and scientific complexity continue to grow, that integration becomes increasingly important for maintaining response quality, regulatory compliance and audit readiness. **QbD Group combines Medical Information and Pharmacovigilance expertise to help pharmaceutical and biotech companies build connected processes across inquiry handling, safety escalation, case management and governance.** Looking to strengthen the connection between your Medical Information and Pharmacovigilance activities? [Explore our Medical Information Services](/en/services/pharmacovigilance/comprehensive-medical-information-services) and discover how QbD Group can support an integrated, compliant operating model. ## References - [European Medicines Agency (EMA) - Guideline on good pharmacovigilance practices (GVP), Module VI: Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev. 2)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports-suspected-adverse-reactions-medical-products-rev-2_en.pdf) - [European Medicines Agency (EMA) - Good pharmacovigilance practices (GVP), overview page](https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/good-pharmacovigilance-practices-gvp) - [UK Medicines and Healthcare products Regulatory Agency (MHRA) - Pharmacovigilance Inspection Metrics Report, April 2019 to March 2020](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/965496/MHRA_GPvP_Inspection_metrics_2019-20.pdf) - [GOV.UK - Good pharmacovigilance practice (GPvP), MHRA guidance overview](https://www.gov.uk/guidance/good-pharmacovigilance-practice-gpvp) --- Source: https://qbdgroup.com/en/blog/medical-information-pharmacovigilance-integration — © QbD Group. Quote freely with attribution and a link back.